Halberd Corporation HALB

HALB Company Overview

Halberd Corporation is a U.S.-based biotechnology and medical technology company traded on the OTC Markets under the ticker HALB. The company has publicly stated that it is focused on developing treatments and diagnostic technologies targeting infectious diseases, neurological conditions, and certain chronic or treatment-resistant disorders. Its activities have included research related to extracorporeal blood filtration systems, antibody-based technologies, and approaches intended to eliminate pathogens or inflammatory agents from the bloodstream. Public disclosures and company communications indicate that the company operates primarily within the biotechnology, medical device, and life sciences sectors.

Halberd’s primary business focus has centered on early-stage research and intellectual property development rather than large-scale commercialized product sales. Public filings indicate that the company has pursued technologies involving laser-based pathogen eradication, monoclonal antibody applications, and neurological treatment concepts associated with post-traumatic stress disorder (PTSD) and other neurological conditions. Based on available public information, the company remains in a developmental stage with limited reported operating revenue. Data regarding broad commercial adoption, material market share, or large-scale product commercialization remains inconclusive based on available public sources.